336 related articles for article (PubMed ID: 33666947)
1. Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study.
Ish-Shalom S; Caraco Y; Khazen NS; Gershinsky M; Szalat A; Schwartz P; Arbit E; Galitzer H; Tang JC; Burshtein G; Rothner A; Raskin A; Blum M; Fraser WD
J Bone Miner Res; 2021 Jun; 36(6):1060-1068. PubMed ID: 33666947
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
Khan AA; Rubin MR; Schwarz P; Vokes T; Shoback DM; Gagnon C; Palermo A; Marcocci C; Clarke BL; Abbott LG; Hofbauer LC; Kohlmeier L; Pihl S; An X; Eng WF; Smith AR; Ukena J; Sibley CT; Shu AD; Rejnmark L
J Bone Miner Res; 2023 Jan; 38(1):14-25. PubMed ID: 36271471
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
4. Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism.
Gafni RI; Guthrie LC; Kelly MH; Brillante BA; Christie CM; Reynolds JC; Yovetich NA; James R; Collins MT
J Bone Miner Res; 2015 Nov; 30(11):2112-8. PubMed ID: 25990370
[TBL] [Abstract][Full Text] [Related]
5. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
Lakatos P; Bajnok L; Lagast H; Valkusz Z
Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.
Puliani G; Hasenmajer V; Simonelli I; Sada V; Pofi R; Minnetti M; Cozzolino A; Napoli N; Pasqualetti P; Gianfrilli D; Isidori AM
J Bone Miner Res; 2022 Jul; 37(7):1233-1250. PubMed ID: 35485213
[TBL] [Abstract][Full Text] [Related]
7. Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial.
Saha S; Sreenivas V; Goswami R
J Clin Endocrinol Metab; 2021 Jun; 106(7):2092-2102. PubMed ID: 33616655
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.
Winer KK; Sinaii N; Reynolds J; Peterson D; Dowdy K; Cutler GB
J Clin Endocrinol Metab; 2010 Jun; 95(6):2680-8. PubMed ID: 20392870
[TBL] [Abstract][Full Text] [Related]
9. Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity.
Gafni RI; Langman CB; Guthrie LC; Brillante BA; James R; Yovetich NA; Boyce AM; Collins MT
J Bone Miner Res; 2018 Oct; 33(10):1741-1747. PubMed ID: 29878514
[TBL] [Abstract][Full Text] [Related]
10. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism.
Winer KK; Yanovski JA; Cutler GB
JAMA; 1996 Aug; 276(8):631-6. PubMed ID: 8773636
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.
Winer KK; Ko CW; Reynolds JC; Dowdy K; Keil M; Peterson D; Gerber LH; McGarvey C; Cutler GB
J Clin Endocrinol Metab; 2003 Sep; 88(9):4214-20. PubMed ID: 12970289
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.
Mannstadt M; Clarke BL; Bilezikian JP; Bone H; Denham D; Levine MA; Peacock M; Rothman J; Shoback DM; Warren ML; Watts NB; Lee HM; Sherry N; Vokes TJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5136-5147. PubMed ID: 31369089
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
[TBL] [Abstract][Full Text] [Related]
14. PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.
Palermo A; Santonati A; Tabacco G; Bosco D; Spada A; Pedone C; Raggiunti B; Doris T; Maggi D; Grimaldi F; Manfrini S; Vescini F
J Clin Endocrinol Metab; 2018 Jan; 103(1):271-280. PubMed ID: 29099939
[TBL] [Abstract][Full Text] [Related]
15. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism.
Khan AA; Rejnmark L; Rubin M; Schwarz P; Vokes T; Clarke B; Ahmed I; Hofbauer L; Marcocci C; Pagotto U; Palermo A; Eriksen E; Brod M; Markova D; Smith A; Pihl S; Mourya S; Karpf DB; Shu AD
J Clin Endocrinol Metab; 2022 Jan; 107(1):e372-e385. PubMed ID: 34347093
[TBL] [Abstract][Full Text] [Related]
16. Management of Hypoparathyroidism.
Khan AA; Guyatt G; Ali DS; Bilezikian JP; Collins MT; Dandurand K; Mannstadt M; Murphy D; M'Hiri I; Rubin MR; Sanders R; Shrayyef M; Siggelkow H; Tabacco G; Tay YD; Van Uum S; Vokes T; Winer KK; Yao L; Rejnmark L
J Bone Miner Res; 2022 Dec; 37(12):2663-2677. PubMed ID: 36161671
[TBL] [Abstract][Full Text] [Related]
17. Chronic hypoparathyroidism and treatment with teriparatide.
Marcucci G; Masi L; Cianferotti L; Giusti F; Fossi C; Parri S; Gronchi G; Brandi ML
Endocrine; 2021 Apr; 72(1):249-259. PubMed ID: 33538953
[TBL] [Abstract][Full Text] [Related]
18. [Reduction in requirements of oral calcium and 1-25 dihydroxy vitamin D in patients with post-surgical hypoparathyroidism treated with teriparatide (PTH1-34)].
Gutiérrez-Cerecedo LE; Vergara-López A; Rosas-Barrientos JV; Guillén-González MÁ
Gac Med Mex; 2016; 152(3):322-8. PubMed ID: 27335186
[TBL] [Abstract][Full Text] [Related]
19. PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life.
Santonati A; Palermo A; Maddaloni E; Bosco D; Spada A; Grimaldi F; Raggiunti B; Volpe R; Manfrini S; Vescini F;
J Clin Endocrinol Metab; 2015 Sep; 100(9):3590-7. PubMed ID: 26196949
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.
Tuli G; Buganza R; Tessaris D; Einaudi S; Matarazzo P; de Sanctis L
Endocrine; 2020 Feb; 67(2):457-465. PubMed ID: 31705387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
